Skip to main content
Clinical Trials/NCT04424524
NCT04424524
Completed
Not Applicable

An Implementation Project to Improve the Efficiency of PrEP Delivery in Public Health HIV Care Clinics in Kenya

University of Washington1 site in 1 country746 target enrollmentMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV Prevention
Sponsor
University of Washington
Enrollment
746
Locations
1
Primary Endpoint
Patient wait time
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a pilot facility-based direct-to-pharmacy PrEP refill delivery to streamline care pathway in Kenyan public health HIV facilities implementing PrEP. Data on up to 500 PrEP users will be evaluated to understand delivery efficiency and in-depth interview with users and delivery key informants will be conducted to identify barriers and facilitators of implementation.

Detailed Description

A prospective, pilot implementation evaluation of patient-centered differentiated care service. The core components of the multifaceted implementation strategy include: 1) 3-monthly refills, 2) direct-to-pharmacy refill visits, 3) HIV self-testing (HIVST) while waiting for refills, 4) Rapid risk assessment for ongoing risk, adherence, side effect, and acute HIV symptoms. Clinics will implement either: 1) current PrEP patient flow without any change or 2) a pilot differentiated pharmacy-based follow up PrEP care pathway. Clinics will implement only one delivery model thus eliminating risk for confusion in the clinic about delivery models and permitting a full-scale test of the system, since the efficiency in PrEP delivery is in part at the system level, above and beyond the individual client encounter. For this pilot project designed to primarily test delivery efficiency, feasibility and acceptability of direct-to-pharmacy care pathway at systems level using existing public health infrastructure, pilot and control clinics will be of comparable size selected to reflect the implementation nature of the design. The specific aims are: Aim 1: To evaluate whether a differentiated care model improves the efficiency of PrEP delivery while resulting in equivalent or better: 1) patient waiting time, 2) early PrEP continuation, and 3) adherence. Aim 2: Conduct mixed-methods study to understand patient and provider perception, experiences , feasibility and acceptability of a differentiated PrEP delivery model. Aim 3: Assess the efficiency, cost and cost-effectiveness of a facility-based differentiated PrEP care.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
April 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kenneth K Mugwanya

Assistant Professor, School of Medicine: Global Health

University of Washington

Eligibility Criteria

Inclusion Criteria

  • For HIV-negative participants:
  • Of legal age (≥18 years)
  • Able and willing to provide written informed consent for research component of the project (blood draw for adherence, brief surveys and in-depth qualitative interviews)
  • HIV uninfected based on negative HIV tests, per Kenya national guidelines
  • Currently or previously accessed PrEP at participating HIV clinic
  • For Key delivery informants:
  • Able willing and able to provide consent in order to participate in the survey and qualitative interviews.
  • Works at any of the clinics implementing PrEP delivery. Key informants may include HIV testing service nurses, counselors, clinicians, social workers, or clinic managers.

Exclusion Criteria

  • Not meeting any of the inclusion criteria listed above.

Outcomes

Primary Outcomes

Patient wait time

Time Frame: up to 6 months

Total waiting time at the clinic and contact time with providers measured by time and motion studies

PrEP continuation

Time Frame: up to 6 months

Measured by return to clinic for PrEP refill

PrEP adherence

Time Frame: up to 6 months

Measured objectively through tenofovir levels in dried blood spots at random subset of PrEP visits

Acceptability of user HIV self-testing for PrEP care pathway

Time Frame: up to 6 months

Assessed by the Acceptability of Intervention Psychometric Measure (AIM)

Acceptability of direct-to-pharmacy PrEP care pathway

Time Frame: up to 6 months

Assessed by the Acceptability of Intervention Psychometric Measure (AIM)

Feasibility of direct-to-pharmacy PrEP care pathway

Time Frame: up to 6 months

Assessed by the Feasibility of Intervention Psychometric Measure (FIM)

Secondary Outcomes

  • Barriers to implementation of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics(up to 6 months)
  • Facilitators to implementation of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics(up to 6 months)
  • Fidelity of implementing of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics(up to 6 months)
  • Cost of implementing direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics(up to 6 months)
  • Safety of HIV self-testing(up to 6 moths)
  • Reasons for PrEP discontinuation(up to 6 months)

Study Sites (1)

Loading locations...

Similar Trials